Vancouver, British Columbia / ACCESSWIRE / August 12, 2014 / Vodis Pharmaceuticals Inc. (the "Company" or "Vodis") (CSE: VP / FSE: 1JV)) is pleased to announce that the Honourable John D. Reynolds and the Honourable Larry Campbell have agreed to join the advisory board of Vodis Pharmaceuticals.
A huge proponent of the Four Pillars approach to ending drug abuse, Mr. Campbell ran for Mayor when he felt this strategy was being neglected. In 2002 he was elected by the citizens of Vancouver under the banner of the Coalition of Progressive Electors (COPE) in what was a landslide election. In addition to drug and crime prevention, he was also instrumental in the successful Vancouver bid to host the 2010 Winter Olympic and Paralympic Games.
In August 2005, Mr. Campbell was summoned to the Senate of Canada by Prime Minister Paul Martin. As a Senator, Mr. Campbell has continued his work on drug policy, mental health, and aboriginal issues. In 2009, Mr. Campbell co-authored a book titled A Thousand Dreams: Vancouver's Downtown Eastside and the Fight for its Future with Neil Boyd and Lori Culbert. He holds a Masters Degree in Business Administration (MBA) from City University in Vancouver.
As Minister of Environment in British Columbia Mr. Reynolds chaired the Cabinet Committee on Environment and Land Use, was a member of the Planning and Priorities Committee of Cabinet, Regional and Economic Development Committee of Cabinet, Native Affairs Committee of Cabinet, Cultural Heritage Committee of Cabinet, and the Vancouver International Airport Cabinet Committee. Mr. Reynolds served as the speaker for the British Columbia legislature.
Mr. Reynolds served in the federal parliament of Canada from 1972 to 1976 and from 1997 to 2006. Mr. Reynolds served on many committees in the House of Commons and was the whip of the official opposition. Mr. Reynolds also served as the official opposition house leader and was elected the leader of the opposition in the House of Commons.
Mr. Reynolds served as co-chair of the successful national Conservative Party campaign for the January 23, 2006 federal election. He was appointed as a member of the Queen's Privy Council for Canada on February 6, 2006 and currently serves on the Board of several other leading public companies.
Otto Folprecht, Chief Executive Officer and Director of Vodis, states: "We are extremely proud that these gentlemen, with their extensive public service for Canadians and British Columbians, have decided to join the Board of Advisors for Vodis. Their combined public and private sector expertise will be key for Vodis as it seeks to be one of the leading companies in the medical marijuana sector."
About Vodis Pharmaceuticals
Vodis is one of Canada's foremost brand names in the medical marijuana business. Its products have consistently won or placed at each competition we have entered. The company is well advanced in the MMPR application process to become a Licenced Producer at its state-of-the-art 12,000 square foot facility in Canada.
For further information please contact:
Brian Gusko
CFO & Director
Vodis Pharmaceuticals
104-1037 West Broadway
Vancouver, BC V6H 1E3
direct: 1-866-210-1420 ext. 106
web: http://www.vodis.ca/
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business and trading in the common stock of Newnote Financial Corp. The forward-looking information is based on certain key expectations and assumptions made by the company's management. Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the company can give no assurance that they will prove to be correct. These forward-looking statements are made as of the date of this press release and the company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved or disapproved the content of this press release.